cagrilintide novo nordisk with semaglutide files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management Novo Nordisk: Engineering a Comeback
Novo Nordisk: Engineering a Comeback for a Strong 2026 Trajectory Novo touts CagriSema's win over semaglutide in pivotal diabetes study What to Know about the Experimental GLP 1 Drug CagriSema Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control
Pay in 4 interest-free payments of $5.15 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12



